October 8th 2024
Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.
September 24th 2024
Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.
September 16th 2024
Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.
September 13th 2024
Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.
August 29th 2024
Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.
August 16th 2024
Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma
August 6th 2024
Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.
July 2nd 2024
Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.
February 24th 2024
Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.
April 15th 2022
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier curves.
December 23rd 2021
Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers to use throughout the therapeutic process.
June 29th 2020
Breaking down your oral presentation into specific content-related and delivery-related domains can help you remember what to rehearse and what to include.